Jarl Ulf Jungnelius, MD, joins Isofol Medical’s Board of Directors

Dokument -

Jarl Ulf Jungnelius, MD, joins Isofol Medical’s Board of Directors

Isofol Medical AB today announced that Jarl Ulf Jungnelius, MD, oncologist and Vice President of Oncology, Global Solid Tumors at Celgene, was elected to Isofol Medical’s Board of Directors. Ulf is a member of both the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). He is also a clinical advisor to Karolinska Development AB.
go to media item
Licens:
All rights reserved
Innehållet får bara användas av Mynewsdesk. Det är alltså inte tillåtet för någon annan att ladda ner, kopiera, sprida eller på annat sätt använda Innehållet (annat än för privat bruk i den mån det följer av lag).
Filformat:
.pdf

Kontakter

Anders Rabbe

Presskontakt CEO +46 (0)707 646 500

Jan-Eric Österlund

Presskontakt Executive Chairman + 44 7785 368155

Relaterat innehåll

Jarl Ulf Jungnelius, MD, joins Isofol Medical’s Board of Directors

Isofol Medical AB today announced that Jarl Ulf Jungnelius, MD, oncologist and Vice President of Oncology, Global Solid Tumors at Celgene, was elected to Isofol Medical’s Board of Directors. Ulf is a member of both the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). He is also a clinical advisor to Karolinska Development AB.